

			
AETNA BETTER HEALTH® Coverage Policy/Guideline			
Name:	Oxlumo	Page:	1 of 2
Effective Date:	4/21/2025	Last Review Date:	3/26/2025
Applies to:	☒ Illinois ☒ Florida Kids	☒ New Jersey ☒ Pennsylvania Kids	☒ Maryland ☒ Kentucky PRMD ☒ Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Oxlumo under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.

All other indications are considered experimental/investigational and not medically necessary

Applicable Drug List:

Oxlumo

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- A. Molecular genetic test results demonstrating a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene or liver enzyme analysis results demonstrating absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity.
- B. Chart notes or medical records demonstrating a positive response to therapy (for continuation requests).

Criteria for Initial Approval

Primary hyperoxaluria type 1 (PH1)

Authorization of 12 months may be granted for the treatment of primary hyperoxaluria type 1 (PH1) when ALL the following criteria are met:

- A. Member has a diagnosis of PH1 confirmed by either of the following:
 1. Molecular genetic test results demonstrating a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene.
 2. Liver enzyme analysis results demonstrating absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity.
- B. The requested medication will not be used in combination with nedosiran.

Criteria for Continuation of Therapy

Authorization of 12 months may be granted for members who meet all initial authorization criteria and demonstrate a positive response to therapy (e.g., decrease or normalization in urinary and/or plasma oxalate levels, improvement in kidney function).



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Oxlumo

Page: 2 of 2

Effective Date: 4/21/2025

Last Review Date: 3/26/2025

Applies to: ☒ Illinois ☒ New Jersey ☒ Maryland ☒ Kentucky PRMD
☒ Florida Kids ☒ Pennsylvania Kids ☒ Virginia

Approval Duration and Quantity Restrictions:

Approval Duration: 12 months

Quantity Level Limit:

Medication	Standard Limit	FDA-recommended dosing
Oxlumo (lumasiran) 94.5 mg/0.5 mL single dose vial	4 vials per 90 days	For patients with body weight < 10 kg: 6 mg/kg once monthly for first 3 doses; 3 mg/kg once monthly for maintenance therapy For patients with body weight 10 to < 20 kg: 6 mg/kg once monthly for first 3 doses; 6 mg/kg once every 3 months for maintenance therapy For patients with body weight ≥ 20 kg: 3 mg/kg once monthly for first 3 doses; 3 mg/kg once every 3 months for maintenance therapy

References:

1. Oxlumo [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; September 2023.
2. Niaudet, P. Primary hyperoxaluria. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2024.
3. Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 2005; 25:154.